Citizens analyst David Turkaly lowered the firm’s price target on Tela Bio (TELA) to $3 from $5 and keeps an Outperform rating on the shares. Tela Bio’s two main biologic product platforms provide significant benefits to all constituents and a premium growth profile should eventually be achievable, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TELA: